Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

Descripción del proyecto

Reprogramación de linfocitos T con receptor quimérico para el antígeno para vencer a los tumores sólidos

La terapia con linfocitos T con receptor quimérico para el antígeno (CAR, por sus siglas en inglés), que consiste en modificar genéticamente linfocitos T del paciente para que ataquen a las células cancerosas, ha transformado el tratamiento de las neoplasias hemáticas. Sin embargo, es mucho menos eficaz contra los tumores sólidos, como el cáncer de pulmón, colon o cerebro. Estos tumores se protegen con barreras tisulares densas y moléculas de carbohidratos modificadas en su superficie, que les permiten ocultarse del sistema inmunitario. El proyecto DEGLYCAR-T, financiado por el Consejo Europeo de Investigación, tiene por objeto desarrollar un nuevo tipo de linfocitos T CAR capaces de eliminar esta capa de carbohidratos en el interior del tumor. Al eliminar esta capa protectora, la terapia podría ayudar a las células inmunitarias a reconocer y atacar el tumor con mayor eficacia y, de este modo, posibilitar tratamientos más seguros y eficaces contra los tumores sólidos.

Objetivo

T cells engineered to express tumour-specific chimeric antigen receptors (CAR) proved effective against B-cell tumours. However, as the technology moves to solid cancers, clinical responses have not been as robust. In this setting, several barriers need to be overcome, including poor tumour recognition and a highly immunosuppressive tumour microenvironment (TME). Altered glycosylation is a hallmark of cancer, often manifesting as incomplete synthesis of O-glycans and increased branching of N-glycans. Glycosylation can mask epitopes to antibodies recognition and suppress anticancer immunity. My Unit was the first to report that N-glycans protect tumours from CAR-T cells and that pharmacological inhibition of N-glycosylation improves efficacy of CAR-T cell therapy in solid malignancies. With the aim of generating a single cell product able to safely offset multiple barriers of tumour resistance, I propose to engineer CAR-T cells to locally express an enzyme able to de-glycosylate tumour and TME cells. This goal will be achieved through the selection of a mutant able to deglycosylate the surface proteome of target cells. To regulate its function in CAR-T cells, I plan to test different systems based on the use of specific promoters, the inclusion of artificial miRNA target sequences, or the generation of a transmembrane variant. A deep characterization of the selected product will be performed in mice reconstituted with a human haemopoietic system. This model will allow to study the efficacy and safety of the proposed approach, and to assess its ability to remodel the TME toward a pro-inflammatory state. I believe that this project will have an immediate impact on cancer immunotherapy, will fuel the development of antiviral approaches and will provide new technological platforms. I have a deep knowledge of CAR-T cell therapy and have established a great network in the field. Despite ambitious, I believe I have the right skills and tools to make this project a reality.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2022-STG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

OSPEDALE SAN RAFFAELE SRL
Aportación neta de la UEn
€ 1 500 000,00
Dirección
VIA OLGETTINA 60
20132 Milano
Italia
Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 500 000,00

Beneficiarios (1)